# Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)

> **NCT01075984** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 279 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** Posaconazole
- **DRUG:** Dextrose 5% in water

## Key facts

- **NCT ID:** NCT01075984
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-23
- **Primary completion:** 2012-11-20
- **Final completion:** 2012-11-20
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075984, "Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01075984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*